Monday, January 9, 2017
SRS (radiation) better WITH ipi (immunotherapy) rather than AFTER in melanoma generally, and brain mets specifically
Radiation WITH immunotherapy (or just prior to) has become a treatment researchers have come to recognize as much more effective in melanoma than either therapy alone.
Here is one post from December that includes links and even more links to a number of articles that make that clear: Immunotherapy (and ipi) better with radiation: AGAIN!
Some of these reports focus on the improved outcomes of the combo vs the components alone. But it is also clear in some of these that folks do better when radiation is given prior to or WITH immunotherapy - rather than when radiation is given AFTER. Now there's this:
The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab. Cohen-Inbar, Shih, Xu, et al. J Neurosurg. 2017 Jan 6.
Melanoma represents the third most common cause of CNS metastases. Immunotherapy has evolved as a treatment option for patients with Stage IV melanoma. Stereotactic radiosurgery (SRS) also elicits an immune response within the brain and may interact with immunotherapy. The authors report on a cohort of patients treated for brain metastases with immunotherapy and evaluate the effect of SRS timing on the intracranial response. All consecutively treated melanoma patients receiving ipilimumab and SRS for treatment of brain metastases at the University of Virginia between 2009 and 2014 were included in this retrospective analysis; data from 46 patients harboring 232 brain metastases were reviewed. The median duration of clinical follow-up was 7.9 months (range 3-42.6 months). The median age of the patients was 63 years (range 24.3-83.6 years). Thirty-two patients received SRS before or during ipilimumab cycles (Group A), whereas 14 patients received SRS after ipilimumab treatment (Group B). Radiographic and clinical responses were assessed at approximately 3-month intervals after SRS. The 2 cohorts were comparable in pertinent baseline characteristics with the exception of SRS timing relative to ipilimumab. Local recurrence-free duration (LRFD) was significantly longer in Group A (median 19.6 months, range 1.1-34.7 months) than in Group B patients (median 3 months, range 0.4-20.4 months). Post-SRS perilesional edema was more significant in Group A. The effect of SRS and ipilimumab on LRFD seems greater when SRS is performed before or during ipilimumab treatments. The timing of immunotherapy and SRS may affect LRFD and postradiosurgical edema. The interactions between immunotherapy and SRS warrant further investigation so as to optimize the therapeutic benefits and mitigate the risks associated with multimodality, targeted therapy.
Folks clearly did better when SRS was given before or during treatment with ipi, though there was an increased incidence of perilesional swelling for those patients. However a median recurrence-free duration of: 19.6 months vs 3 months!!!! Hhmmmmmm....
On the topic of brain mets, here is a link to a nice review of treatment (Thanks, Eric!): Online library.wiley.com - Melanoma central nervous system metastases: current approaches, challenges, and opportunities
Wishing you all my best. - c